The market has climbed 1.7% in the last 7 days and 12% over the past year, with earnings forecasted to grow by 14% annually. Even as some investors focus on larger, established companies, penny stocks remain a compelling area for those seeking growth opportunities at lower price points. These smaller or newer companies can offer significant potential when they possess strong balance sheets and solid fundamentals, making them worthy of consideration for those looking to uncover hidden value in today's market.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Perfect (NYSE:PERF) | $1.82 | $185.36M | ✅ 4 ⚠️ 0 View Analysis > |
| WM Technology (NasdaqGS:MAPS) | $1.04 | $174.9M | ✅ 4 ⚠️ 1 View Analysis > |
| Flexible Solutions International (NYSEAM:FSI) | $4.41 | $55.78M | ✅ 1 ⚠️ 2 View Analysis > |
| TETRA Technologies (NYSE:TTI) | $2.68 | $356.64M | ✅ 4 ⚠️ 2 View Analysis > |
| Imperial Petroleum (NasdaqCM:IMPP) | $2.86 | $98.43M | ✅ 4 ⚠️ 2 View Analysis > |
| Table Trac (OTCPK:TBTC) | $4.75 | $22.04M | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (OTCPK:BABB) | $0.8116 | $5.9M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (NasdaqGS:LCUT) | $3.33 | $74.64M | ✅ 3 ⚠️ 2 View Analysis > |
| New Horizon Aircraft (NasdaqCM:HOVR) | $1.06 | $33.27M | ✅ 4 ⚠️ 5 View Analysis > |
| Greenland Technologies Holding (NasdaqCM:GTEC) | $1.97 | $34.27M | ✅ 2 ⚠️ 5 View Analysis > |
Click here to see the full list of 730 stocks from our US Penny Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Cytek Biosciences (NasdaqGS:CTKB)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Cytek Biosciences, Inc. is a cell analysis solutions company offering tools that advance biomedical research and clinical applications, with a market cap of $350.85 million.
Operations: The company generates revenue from its Scientific & Technical Instruments segment, which amounted to $197.05 million.
Market Cap: $350.85M
Cytek Biosciences, with a market cap of US$350.85 million, is navigating the penny stock landscape by leveraging its innovative cell analysis solutions. Despite being unprofitable and facing a net loss of US$11.4 million in Q1 2025, Cytek maintains a strong cash position with short-term assets exceeding liabilities and sufficient runway for over three years due to positive free cash flow growth. Recent product launches like the Cytek Aurora Evo system highlight its commitment to advancing research tools, potentially enhancing market positioning amidst evolving industry demands. However, challenges persist as revenue guidance suggests modest growth amid increased competition and operational losses.
- Click here to discover the nuances of Cytek Biosciences with our detailed analytical financial health report.
- Explore Cytek Biosciences' analyst forecasts in our growth report.
Blend Labs (NYSE:BLND)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Blend Labs, Inc. operates a cloud-based software platform catering to financial services firms in the United States, with a market cap of approximately $946.19 million.
Operations: The company's revenue is derived from its cloud-based platform, generating $118.69 million, with an additional segment adjustment of $46.26 million.
Market Cap: $946.19M
Blend Labs, Inc., with a market cap of approximately US$946.19 million, is making strides in the penny stock arena by enhancing its cloud-based platform for financial services. Despite being unprofitable, it has reduced losses over the past five years and maintains a stable cash runway exceeding three years. Recent initiatives include launching a Business Deposit Account Opening solution and integrating with Glia for improved customer interactions. The company reported Q1 2025 revenue of US$26.77 million, up from the previous year, alongside guidance projecting increased platform revenue next quarter. Additionally, Blend completed a share buyback program worth US$3.07 million this year.
- Navigate through the intricacies of Blend Labs with our comprehensive balance sheet health report here.
- Examine Blend Labs' earnings growth report to understand how analysts expect it to perform.
Waterdrop (NYSE:WDH)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Waterdrop Inc. operates as an online insurance brokerage in China, connecting users with insurance products, and has a market cap of approximately $524.41 million.
Operations: The company's revenue is primarily derived from its insurance segment, which generated CN¥2.56 billion, complemented by its crowd funding segment with CN¥155.80 million.
Market Cap: $524.41M
Waterdrop Inc., with a market cap of approximately US$524.41 million, stands out in the penny stock sector due to its robust financial performance and strategic initiatives. The company has demonstrated significant earnings growth, with net profit margins improving from 6.4% to 13.3% over the past year, and earnings growing by a very large margin of 119.8%. Waterdrop's board and management are seasoned, which supports its stable operations. Recent activities include completing share buybacks worth US$13.7 million and distributing dividends totaling approximately US$7.3 million, reflecting confidence in its financial health and commitment to shareholder value.
- Click here and access our complete financial health analysis report to understand the dynamics of Waterdrop.
- Understand Waterdrop's earnings outlook by examining our growth report.
Make It Happen
- Click through to start exploring the rest of the 727 US Penny Stocks now.
- Interested In Other Possibilities? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Waterdrop might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com